Antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer

Published Date: 03 Jun 2025

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to data ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

After a plane crash, a surgeon dies; Austin is released from the hospital; and an animal pandemic spreads.

2.

New target points to combination therapy for thwarting multidrug resistance in cancer treatment

3.

Telehealth in the pandemic era resulted in fewer therapy interruptions.

4.

Survivors of childhood brain cancer are more likely to be held back in school

5.

For elderly, unfit patients, the all-oral AML regimen shows promise.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot